Susan H. Alexander Sells 4,974 Shares of Biogen Inc. (NASDAQ:BIIB) Stock
Biogen Inc. (NASDAQ:BIIB) EVP Susan H. Alexander sold 4,974 shares of the stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $290.01, for a total value of $1,442,509.74. Following the transaction, the executive vice president now directly owns 22,258 shares of the company’s stock, valued at approximately $6,455,042.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Biogen Inc. (BIIB) traded up 4.47% on Wednesday, reaching $295.61. The company’s stock had a trading volume of 3,014,256 shares. The firm has a 50 day moving average price of $270.82 and a 200 day moving average price of $273.59. Biogen Inc. has a 52 week low of $244.28 and a 52 week high of $307.76. The stock has a market capitalization of $62.70 billion, a P/E ratio of 18.51 and a beta of 0.78.
Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Tuesday, July 25th. The biotechnology company reported $5.04 EPS for the quarter, topping analysts’ consensus estimates of $4.36 by $0.68. Biogen had a net margin of 30.17% and a return on equity of 38.17%. The firm had revenue of $3.08 billion for the quarter, compared to analyst estimates of $2.81 billion. During the same quarter in the previous year, the business posted $5.21 EPS. The firm’s revenue was up 6.4% compared to the same quarter last year. On average, equities analysts anticipate that Biogen Inc. will post $20.96 EPS for the current year.
WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/26/susan-h-alexander-sells-4974-shares-of-biogen-inc-nasdaqbiib-stock.html.
A number of institutional investors have recently modified their holdings of the company. BlackRock Inc. raised its position in shares of Biogen by 2,762.0% in the first quarter. BlackRock Inc. now owns 17,692,259 shares of the biotechnology company’s stock worth $4,837,418,000 after buying an additional 17,074,075 shares in the last quarter. Janus Capital Management LLC raised its position in shares of Biogen by 204.8% in the first quarter. Janus Capital Management LLC now owns 1,936,719 shares of the biotechnology company’s stock worth $529,524,000 after buying an additional 1,301,251 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Biogen by 2,288.0% in the first quarter. Massachusetts Financial Services Co. MA now owns 1,352,164 shares of the biotechnology company’s stock worth $369,709,000 after buying an additional 1,295,540 shares in the last quarter. Winslow Capital Management LLC purchased a new position in shares of Biogen during the first quarter worth approximately $345,143,000. Finally, Manning & Napier Advisors LLC raised its position in shares of Biogen by 563.8% in the second quarter. Manning & Napier Advisors LLC now owns 814,369 shares of the biotechnology company’s stock worth $220,986,000 after buying an additional 691,694 shares in the last quarter. Hedge funds and other institutional investors own 87.50% of the company’s stock.
BIIB has been the subject of a number of research analyst reports. Leerink Swann set a $300.00 target price on Biogen and gave the company a “hold” rating in a report on Monday, April 3rd. Vetr raised Biogen from a “buy” rating to a “strong-buy” rating and set a $311.67 target price for the company in a report on Tuesday, June 27th. Deutsche Bank AG initiated coverage on Biogen in a report on Friday, June 23rd. They set a “buy” rating and a $315.00 target price for the company. Cowen and Company reissued a “buy” rating and set a $338.00 target price on shares of Biogen in a report on Tuesday, April 25th. Finally, Barclays PLC reissued an “overweight” rating and set a $360.00 target price (down previously from $380.00) on shares of Biogen in a report on Sunday, April 23rd. Thirteen investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $327.49.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.